Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Hompesch

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Journal of Diabetes Science and Technology|July 5, 2011
Biosimilar insulins: how similar is similar?Lutz Heinemann, Marcus Hompesch
Journal of Diabetes Science and Technology|May 31, 2014
Biosimilar Insulins: Basic ConsiderationsLutz Heinemann, Marcus Hompesch
Journal of Diabetes Science and Technology|November 4, 2009
Role of physicians in the pharmaceutical industry and clinical research organizations: take more pride in your workLutz Heinemann, Marcus Hompesch
Journal of Diabetes Science and Technology|November 4, 2009
An analysis of how to measure glucose during glucose clamps: are glucose meters ready for research?Marcus Hompesch, Klaus Rave
Biomarkers in Medicine|October 14, 2016
Glucose: archetypal biomarker in diabetes diagnosis, clinical management and researchAndrew J Krentz, Marcus Hompesch
Diabetes Technology & Therapeutics|August 24, 2004
Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulinChristoph Kapitza, Marcus Hompesch, Birgitte Scharling, et al.
Journal of Diabetes Science and Technology|July 6, 2016
Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled InsulinLutz Heinemann, Robert Baughman, Anders Boss, et al.
Diabetes Care|January 29, 2011
Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidaseMarcus Hompesch, Douglas B Muchmore, Linda Morrow, et al.
Postgraduate Medicine|January 30, 2019
Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetesMarcus Hompesch, Dhiren K Patel, James R LaSalle, et al.
Diabetes, Obesity & Metabolism|June 13, 2023
Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight and obese patients with co-morbiditiesWonjung Shin, Marcus Hompesch, JinHee Byeon, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Journal of Diabetes Science and Technology|July 5, 2011
Biosimilar insulins: how similar is similar?Lutz Heinemann, Marcus Hompesch
Journal of Diabetes Science and Technology|May 31, 2014
Biosimilar Insulins: Basic ConsiderationsLutz Heinemann, Marcus Hompesch
Journal of Diabetes Science and Technology|November 4, 2009
Role of physicians in the pharmaceutical industry and clinical research organizations: take more pride in your workLutz Heinemann, Marcus Hompesch
Journal of Diabetes Science and Technology|November 4, 2009
An analysis of how to measure glucose during glucose clamps: are glucose meters ready for research?Marcus Hompesch, Klaus Rave
Biomarkers in Medicine|October 14, 2016
Glucose: archetypal biomarker in diabetes diagnosis, clinical management and researchAndrew J Krentz, Marcus Hompesch
Diabetes Technology & Therapeutics|August 24, 2004
Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulinChristoph Kapitza, Marcus Hompesch, Birgitte Scharling, et al.
Journal of Diabetes Science and Technology|July 6, 2016
Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled InsulinLutz Heinemann, Robert Baughman, Anders Boss, et al.
Diabetes Care|January 29, 2011
Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidaseMarcus Hompesch, Douglas B Muchmore, Linda Morrow, et al.
Postgraduate Medicine|January 30, 2019
Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetesMarcus Hompesch, Dhiren K Patel, James R LaSalle, et al.
Diabetes, Obesity & Metabolism|June 13, 2023
Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight and obese patients with co-morbiditiesWonjung Shin, Marcus Hompesch, JinHee Byeon, et al.
Pageof 6